A comprehensive review of the recent advancements in the development of a dengue vaccine: in the hour of need
Abstract
Dengue fever, caused by the Dengue virus (DENV), remains a critical public health challenge, particularly in tropical and subtropical regions. Despite advancements in vaccine development, achieving an effective and universally safe vaccine remains complex due to the presence of four distinct serotypes (DENV-1 to DENV-4), which contribute to antibody-dependent enhancement (ADE) and inconsistent immune responses. Current vaccines, such as Dengvaxia, TAK-003 (QDENGA®), and TV003/TV005, demonstrate varying efficacy and safety profiles, necessitating further research into balanced immunity, reduced ADE risk, and global accessibility. This review aims to bridge the knowledge gaps present in existing literature by providing a comprehensive analysis of dengue vaccine development, challenges in implementation, and potential future strategies. It seeks to provide a detailed and updated analysis of the advancements in dengue vaccine development, identifying gaps in existing studies and highlighting strategies to overcome current challenges in achieving a safe and effective vaccine. The review includes an examination of the epidemiology and immunology of dengue fever and its impact on global health, an evaluation of the progress and limitations of existing dengue vaccines, including Dengvaxia, TAK-003, and TV003/TV005, an analysis of the challenges in vaccine development such as ADE, serotype-specific immunity, and accessibility in endemic regions, and a discussion of emerging vaccine platforms, including mRNA-based and vector-based approaches. Additionally, it proposes recommendations for future research and policy strategies for improved vaccine deployment and disease management. Through an exhaustive review of existing research, this article aims to contribute valuable insights to the scientific community, fostering further innovation in dengue vaccine development and public health strategies. Key words: Dengue Virus, Dengue Fever, Antibody Dependent Enhancement, Chimeric Yellow Fever-Dengue-Tetravalent Dengue Vaccine, Takeda, Antigen-Antibody, Cluster of Differentiation, Virologically Confirmed Dengue, Dengue Purified Inactivated Vaccine, Tetravalent Dengue DNA Vaccine.
Keywords:
Dengue Virus, Dengue Fever, Antibody Dependent Enhancement, Chimeric Yellow Fever-Dengue-Tetravalent Dengue Vaccine, Takeda, Antigen-AntibodyDOI
https://doi.org/10.22376/ijpbs.v16i2.39References
1. Sheng-Qun Deng, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang and Hong-Juan Peng, A Review on Dengue Vaccine Development, Vaccines (Basel). 2020 Mar; 8(1): 63.
2. Jesús M. TorresFlores, Arturo ReyesSandoval, Ma Isabel Salazar, Dengue Vaccines: An Update, BioDrugs. 2022; 36(3): 325–336.
3. AnshulaTayal, Sushil Kumar Kabra, Rakesh Lodha, Management of Dengue: An Updated Review, Indian J Pediatr. 2023; 90(2): 168–177.
4. Danielle Tully and Carrie L. Griffiths, Dengvaxia: the world’s first vaccine for prevention of secondary dengue, TherAdv Vaccines Immunother. 2021; 9: 25151355211015839.
5. Eriberto Noel Natali, Alexander Horst, Patrick Meier, Victor Greiff, Mario Nuvolone, Lmar Marie Babrak, Katja Fink and Enkelejda Miho, The dengue-specific immune response and antibody identification with machine learning, npj Vaccines (2024)9:16 ; https://doi.org/10.1038/s41541-023-00788-7
6. Monica Palanichamy Kala, Ashley L. St. John, Abhay P. S. Rathore, Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines, Curr Treat Options Infect Dis (2023) 15:27–52
7. JéssicaPires Farias, Alexander Birbrair, and Jaime Henrique Amorim, Advancing dengue vaccination using a T-cell priming peptide approach, eBioMedicine. 2024 Mar; 101: 105012.
8. Esper G. Kallás, M.D., Ph.D., Monica A.T. Cintra, M.D., Ph.D., José A. Moreira, M.D., Ph.D., Elizabeth G. Patiño, Ph.D., Patricia Emilia Braga, Ph.D., Juliana C.V. Tenório, Ph.D., Vanessa Infante, M.D., and Mauricio L. Nogueira, M.D., Ph.D., Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults, N Engl J Med 2024;390:397-408
9. Gabriela Paz-Bailey, MD, PhD,Laura Adams, DVM,Joshua M. Wong, MD,Katherine A. Poehling, MD,Wilbur H. Chen, MD,Veronica McNally, JD,Robert L. Atmar, MD,and Stephen H. Waterman, MD, Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021, MMWR Recomm Rep. 2021 Dec 17; 70(6): 1–16.
10. RuwandiKariyawasam, Mark Lachman, Saniya Mansuri, SumontraChakrabarti, Andrea K. Boggild, A dengue vaccine whirlwind update, TherAdv Infect Dis. 2023 Jan-Dec; 10: 20499361231167274.
11. Stephen J. Thomas, Is new dengue vaccine efficacy data a relief or cause for concern? npj Vaccines (2023) 8:55
12. Christine A. King, Adam D. Wegman and Timothy P. Endy, Mobilization and Activation of the Innate Immune Response to Dengue Virus, Front. Cell. Infect. Microbiol. 10:574417
13. Laura A. Byk and Andrea V. Gamarnik, Properties and Functions of the Dengue Virus Capsid Protein, Annu Rev Virol. 2016 Sep 29; 3(1): 263–281
14. ArshiKhanam, Hector Gutiérrez-Barbosa, Kirsten E. Lyke, Joel V. Chua, Immune-Mediated Pathogenesis in Dengue Virus Infection, Viruses 2022, 14(11), 2575;
15. Yong YK, Wong WF, Vignesh R, Chattopadhyay I, Velu V, Tan HY, Zhang Y, Larsson M and Shankar EM (2022) Dengue Infection –Recent Advances in Disease Pathogenesis in the Era of COVID-19. Front. Immunol. 13:889196.
16. Rakshit K Singh, Aakriti Tiwari, Prasiddhi D Satone, TannuPriya, and Revat J Meshram, Updates in the Management of Dengue Shock Syndrome: A Comprehensive Review, Cureus. 2023 Oct; 15(10): e46713.
17. Maria Elena Flacco, Alessandro Bianconi, Giovanni Cioni, Matteo Fiore, Giovanna LetiziaCalò, GianmarcoImperiali, Vittorio Orazi, Marco Tiseo, Anastasia Troia, Annalisa Rosso, LambertoManzoli, Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis, Vaccines (Basel). 2024 Jul 13;12(7):770.
18. Angelin, Martin, Jan Sjölin, Fredrik Kahn, Anna LjunghillHedberg, AnjaRosdahl, Paul Skorup, Simon Werner, Susanne Woxenius, and Helena H. Askling. "Qdenga®-A promising dengue fever vaccine; can it be recommended to non-immune travelers?." Travel Medicine and Infectious Disease 54 (2023): 102598.
19. Zhu, Yan, Deborah J. Mills, Christine Mills, Colleen L. Lau, and Luis Furuya-Kanamori. "Use of Dengvaxia® in Australian travellers: a case series." Journal of Travel Medicine 31, no. 4 (2024).
20. Halstead, Scott B. "Three dengue vaccines—what now." N. Engl. J. Med 390 (2024): 464-465.
21. Dai, Yu-Ching, Ava Kristy Sy, Mario Jiz, Jih-Jin Tsai, Joan Bato, Mary Ann Quinoñes, Mary Anne Joy Reyes, and Wei-Kung Wang. "Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines." Frontiers in immunology 14 (2023): 1202055.
22. Pintado Silva, Jessica, and Ana Fernandez-Sesma. "Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art." Journal of General Virology 104, no. 3 (2023): 001831.
23. Liu, Xiaoyang, and Daniel Salmon. "Opportunities and challenges of mRNA technologies in development of Dengue Virus Vaccine." arXiv preprint arXiv:2409.10805 (2024).
24. Silva, Jessica Pintado. "Immunogenicity of the NIAID’s Live Attenuated Tetravalent Dengue Vaccine in Primary Human Systems." PhD diss., Icahn School of Medicine at Mount Sinai, 2023.
25. Chowdhury, Fazle Rabbi, QuaziMamtaz Uddin Ahmed, and Shrebash Paul. "The Quest for an Effective Dengue Vaccine: Hope or Hype." Journal of Medicine 25, no. 1 (2024): 58-67
26. Pintado Silva and Fernandez-Sesma, Journal of General Virology2023;104:001831 DOI10.1099/jgv.0.001831
Published

